Full Breakdown
AIG Hospitals Launches Affordable Pharmacogenomics Test in Hyderabad
10/24/2025, 1:24:51 PM
Introduction to Pharmacogenomics Testing
AIG Hospitals in Hyderabad, in collaboration with GenepoweRx, has introduced India’s first affordable pharmacogenomics test, aimed at personalizing medication prescriptions based on individual genetic profiles. Priced at INR5,000, this test significantly undercuts the INR80,000 typically charged for similar tests in Western countries. The initiative is designed to help doctors prescribe medications that align with a patient's unique genetic makeup, enhancing treatment efficacy and minimizing adverse drug reactions.
Core Event: Launch of the Pharmacogenomics Test
The pharmacogenomics test analyzes a patient's DNA to predict their response to various medications, including those for heart disease, diabetes, cancer, and psychiatric conditions. A study involving over 2,000 patients revealed that nearly 30% were prescribed medications unsuitable for their genetic profiles, leading to ineffective treatments or harmful side effects. The test evaluates approximately 120–190 genes influencing drug metabolism, providing a comprehensive overview that remains relevant for future medical needs.
How the Test Works
The testing process involves drawing a 2 ml blood sample, from which DNA is extracted and analyzed using advanced sequencing technologies. Results are compiled into a personalized report delivered within 12–13 days, allowing patients to share this information with any healthcare provider globally. This ensures that all future prescriptions are tailored to the individual's genetic compatibility, promoting a shift from standardized to personalized medicine.
Cost and Benefits
Dr. D. Nageshwar Reddy, chairman of AIG Hospitals, emphasized that the test not only enhances treatment outcomes but also reduces overall healthcare costs by preventing over-prescription and unnecessary high dosages. By addressing genetic variations specific to the Indian population, the test aims to improve patient safety and reduce the burden of adverse drug reactions, which are a leading cause of hospitalizations.
Criticism & Opposition
While the initiative has been praised for its potential to revolutionize healthcare in India, some experts express concerns regarding the widespread implementation of pharmacogenomics. They highlight the need for adequate training among healthcare providers to interpret genetic data effectively and ensure that the test is integrated into routine clinical practice.
Official Statements & Responses
Dr. Reddy stated, “At AIG Hospitals, we believe that every Indian deserves access to personalized, evidence-based treatment, not trial and error.” He further noted that this initiative could serve as a foundation for large-scale genomic and translational research in India, aiming to make precision medicine a standard part of healthcare.
What's Next
The launch of this pharmacogenomics test marks a significant step toward integrating precision medicine into Indian healthcare. AIG Hospitals plans to expand its genomic testing capabilities and collaborate with other institutions to enhance research and development in this field, potentially setting a precedent for similar initiatives across the country.
Conclusion: A New Era in Indian Healthcare
The introduction of the pharmacogenomics test at AIG Hospitals represents a pivotal moment for personalized medicine in India. By making advanced genetic testing accessible and affordable, this initiative not only promises to improve treatment outcomes but also positions Hyderabad as a national hub for precision medicine, paving the way for a more individualized approach to healthcare.
